按類型、治療方法、階段、給藥途徑和地區分類的老齡化黃斑部病變治療市場規模、佔有率和成長分析 - 行業預測（2026-2033 年）

全球老齡化黃斑部病變治療市場規模預計在 2024 年達到 181.2 億美元，從 2025 年的 196.6 億美元成長到 2033 年的 377.6 億美元，在預測期（2026-2033 年）內複合年成長率為 8.5%。

由於老齡化黃斑部病變黃斑部病變（AMD）盛行率不斷上升以及人口老化，全球老齡化治療市場正經歷快速成長。該領域致力於透過滿足未被滿足的需求來改善患者的生活品質。關鍵的成長要素包括抗血管內皮生長因子（抗VEGF）療法和緩釋性藥物遞送系統等治療技術的進步，這些進步顯著改善了患者的治療效果。此外，人們對早期檢測重要性的認知不斷提高，也推動了對有效治療方法的需求。然而，高昂的治療成本和監管方面的挑戰依然存在。值得關注的趨勢包括：聯合治療的興起，這些療法能夠有效靶向多種疾病路徑；以及新型基因治療方法的出現。在人工智慧和機器學習在個人化醫療領域的進步支持下，尤其是在亞太和拉丁美洲等地區，存在著巨大的未開發機會。

推動全球老齡化黃斑部病變治療市場發展的因素

老齡化黃斑部病變（AMD）治療市場受到人口老化加劇的顯著影響。由於該疾病主要影響50歲及以上人口，隨著全球老年人口的成長， 黃斑部病變老齡化將上升。全球人口趨勢顯示黃斑部病變人口將顯著成長，因此對有效治療方法的需求預計將大幅成長。這種轉變凸顯了開發創新治療方案以應對老齡化挑戰的必要性，從而推動市場成長，並促進針對該族群的治療方法和醫療保健解決方案的進步。

限制全球老齡化黃斑部病變治療市場的因素

由於嚴格的監管要求和漫長的新治療方法核准流程，全球老齡化黃斑部病變治療市場面臨嚴峻挑戰。創新療法的研發需要大規模的臨床試驗、全面的安全性評估和詳盡的監管申報，所有這些都耗費了大量的時間和金錢。這種複雜的監管環境可能會阻礙一些製藥公司在該領域進行研發，從而限制新療法的上市。這可能導致新療法的研發進展緩慢，並阻礙患者獲得先進的黃斑部病變治療方法。

全球老齡化黃斑部病變治療市場趨勢

全球老齡化黃斑部病變)治療市場正日益受到遠端醫療和遠端監測技術的影響。這些技術正在改變患者照護模式，實現對視力和疾病進展的遠端評估，從而最大限度地減少頻繁的面對面就診。透過利用居家視力檢查和智慧型手機影像設備，醫療服務提供者可以確保及時介入和更好地管理疾病，從而提高患者的便利性並最佳化醫療成本。這種向數位化解決方案的轉變標誌著醫療實踐的演進，並凸顯了老齡化治療領域致力於在黃斑部病變治療通訊協定的同時改善患者預後的決心。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究
• 技術進步

全球老齡化黃斑部病變治療市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 乾性老齡化黃斑部病變
• 濕性老齡化黃斑部病變
• 其他

全球老齡化黃斑部病變治療市場規模（依治療方法分類）及複合年成長率（2026-2033 年）

• 抗血管內皮生長因子
• 其他

全球老齡化黃斑部病變治療市場規模（按階段和複合年成長率分類）（2026-2033 年）

• 早期老齡化黃斑部病變（AMD）
• 過渡時期老齡化黃斑部病變（AMD）
• 晚期老齡化黃斑部病變（AMD）

全球老齡化黃斑部病變治療市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 靜脈注射途徑
• 玻璃體內注射途徑

全球老齡化黃斑部病變治療市場規模（按通路分類）及複合年成長率（2026-2033 年）

• 門診手術中心
• 醫院
• 其他分銷管道

全球老齡化黃斑部病變治療市場規模（按地區分類）及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Pfizer Inc.（United States）
• Regeneron Pharmaceuticals Inc.（United States）
• AbbVie Inc.（United States）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch Health Companies Inc.（Canada）
• Amgen Inc.（United States）
• Biogen Inc.（United States）
• Samsung Bioepis（South Korea）
• PanOptica（United States）
• REGENXBIO Inc.（United States）
• Lineage Cell Therapeutics（United States）
• Ocugen Inc.（United States）
• Olix Pharmaceuticals Inc.（South Korea）
• ONL Therapeutics（United States）
• MeiraGTx（United States）
• OnPoint Vision Inc.（United States）
• Alcon（Switzerland）

結論與建議

Global Macular Degeneration Treatment Market size was valued at USD 18.12 Billion in 2024 and is poised to grow from USD 19.66 Billion in 2025 to USD 37.76 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The global macular degeneration treatment market is experiencing rapid growth, driven by the increasing prevalence of age-related macular degeneration (AMD) and an aging population. This sector focuses on enhancing patient quality of life by addressing significant unmet medical needs. Key growth drivers include advancements in treatment technologies like anti-vascular endothelial growth factor (anti-VEGF) therapies and sustained-release drug delivery systems, which improve outcomes for patients. Additionally, heightened awareness of early detection boosts demand for effective therapies. However, obstacles such as high treatment costs and regulatory challenges persist. Noteworthy trends involve the rise of combination therapies that effectively target multiple disease pathways and emerging gene therapy approaches. Significant opportunities lie within untapped markets, particularly in regions like Asia-Pacific and Latin America, supported by advancements in AI and machine learning for personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macular Degeneration Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macular Degeneration Treatment Market Segments Analysis

Global Macular Degeneration Treatment Market is segmented by Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration and Others. Based on Treatment, the market is segmented into Anti-vascular Endothelial and Others. Based on Stage of Disease, the market is segmented into Early-stage AMD, Intermediate AMD and Late-stage AMD. Based on Route of Administration, the market is segmented into Intravenous Route and Intravitreal Route. Based on Distribution Channel, the market is segmented into Ambulatory Surgical Centres, Hospitals and Other Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macular Degeneration Treatment Market

The macular degeneration treatment market is significantly influenced by the growing aging population. As this condition predominantly impacts individuals over 50, the increasing number of older adults worldwide is anticipated to lead to a higher incidence of macular degeneration. With the global demographic trends indicating a substantial rise in the elderly population, the demand for effective treatments is expected to surge. This shift emphasizes the need for innovative therapeutic options to address the challenges posed by age-related macular degeneration, thereby driving market growth and encouraging advancements in treatment methodologies and healthcare solutions tailored to this demographic.

Restraints in the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market faces significant challenges due to stringent regulatory requirements and protracted approval processes for new therapies. The development of innovative treatment options necessitates extensive clinical trials, thorough safety assessments, and comprehensive regulatory submissions, all of which can be both time-consuming and financially burdensome. This complicated regulatory landscape may discourage some pharmaceutical companies from pursuing research and development in this area, ultimately restricting the introduction of novel treatments into the market. Consequently, the slow progression of new therapies can hinder patient access to advanced care options for macular degeneration.

Market Trends of the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market is increasingly influenced by the rise of telemedicine and remote monitoring technologies, which have transformed patient care dynamics. This trend facilitates remote assessments of vision and disease progression, minimizing the necessity for frequent in-person appointments. By leveraging home-based visual acuity tests and smartphone imaging devices, healthcare providers can ensure timely interventions and better disease management, ultimately enhancing patient convenience and optimizing healthcare costs. This shift towards digital solutions is indicative of evolving healthcare practices, underscoring a commitment to improving patient outcomes while streamlining treatment protocols in the macular degeneration landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Macular Degeneration Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration
• Others

Global Macular Degeneration Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Anti-vascular Endothelial
• Others

Global Macular Degeneration Treatment Market Size by Stage of Disease & CAGR (2026-2033)

• Market Overview
• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Global Macular Degeneration Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous Route
• Intravitreal Route

Global Macular Degeneration Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Ambulatory Surgical Centres
• Hospitals
• Other Channels

Global Macular Degeneration Treatment Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PanOptica (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olix Pharmaceuticals Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONL Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OnPoint Vision Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations